Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11925168 | 0.76 | TSHR (0.38) | CHRM2CHRM3ALDH1A1HPGDNPSR1 | |
| SCHEMBL13199770 | 0.71 | RARA (0.31) | — | |
| SCHEMBL13684330 | 0.71 | KDM4E (0.48) | NPSR1KMT2A | |
| SCHEMBL11912105 | 0.70 | RARA (0.40) | ALDH1A1HPGDNPSR1MEN1KMT2A | |
| SCHEMBL21016822 | 0.67 | ALDH1A1 (0.40) | CHRM2CHRM3ALDH1A1HPGDNPSR1 | |
| SCHEMBL21016809 | 0.67 | ALDH1A1 (0.40) | CHRM2CHRM3ALDH1A1HPGDNPSR1 | |
| SCHEMBL10281244 | 0.66 | CXCR3 (0.34) | CHRM2CHRM3NPSR1 | |
| SCHEMBL20467799 | 0.65 | GAA (0.32) | — | |
| SCHEMBL10299249 | 0.65 | MEN1 (0.36) | ALDH1A1HPGDNPSR1MEN1KMT2A | |
| SCHEMBL13081612 | 0.63 | TSHR (0.50) | ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10464969-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2019-11-05 | — | — | US | disclosed |
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464969-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | RNGTT, RNASE1, RNMT | CHRM2 4628/4885CHRM3 4145/4885ALDH1A1 3142/4885 |
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | CHRM2 4628/4885CHRM3 4145/4885ALDH1A1 3142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.